Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Carna Biosciences's Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was 円-1,054.9 Mil. Therefore, Carna Biosciences's EV-to-EBIT ratio for today is -6.86.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Carna Biosciences's Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was 円-1,054.9 Mil. Therefore, Carna Biosciences's EV-to-EBITDA ratio for today is -6.86.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Carna Biosciences's Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was 円291.4 Mil. Therefore, Carna Biosciences's EV-to-Revenue ratio for today is 24.85.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Carna Biosciences (TSE:4572) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Carna Biosciences's current Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,054.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Carna Biosciences's current Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-1,054.9 Mil.
Carna Biosciences's current Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円291.4 Mil.
Carna Biosciences's current Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.
Carna Biosciences's current Enterprise Value is 円7,239.7 Mil.
Carna Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carna Biosciences Enterprise Value Related Terms
Carna Biosciences Enterprise Value Historical Data
* Premium members only.
The historical data trend for Carna Biosciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4572 vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Carna Biosciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carna Biosciences Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Carna Biosciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Carna Biosciences's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Carna Biosciences's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of 円7,239.7 Mil mean?
Carna Biosciences (TSE:4572) has a Enterprise Value of 円7,239.7 Mil as of Jul. 02, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Enterprise Value too high?
Carna Biosciences' current Enterprise Value is 円7,239.7 Mil. Overall, Carna Biosciences has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Enterprise Value compare to VRTX and REGN?
Carna Biosciences' Enterprise Value of 円7,239.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Enterprise Value is 円7,239.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円174.96, compared to a current price of 円340.00 — trading 94.3% above its estimated fair value. The current Enterprise Value is 円7,239.7 Mil. Carna Biosciences' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Enterprise Value is 円7,239.7 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carna Biosciences (TSE:4572) Overvalued in 2026?
Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued.
The current stock price of 円340.00 is trading 94.3% above its estimated GF Value™ of 円174.96.
GuruFocus considers Carna Biosciences to be Significantly Overvalued.
Key valuation signals for TSE:4572:
Enterprise Value: 円7,239.7 Mil
GF Value™: 円174.96 vs. price of 円340.00 (94.3% above fair value)
No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
24GF Score
Get the complete analysis for TSE:4572
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4572 has been successfully added to your 
